FDA Approves Bayer’s Low-Dose MRI Contrast Agent
The new agent is indicated for visualizing lesions in the central nervous system and other body regions for adult and pediatric patients.
The new agent is indicated for visualizing lesions in the central nervous system and other body regions for adult and pediatric patients.
The five-year project funded by ARPA-H aims to develop ultra-high dose rate cancer treatments using existing linear accelerators.
The cleared system introduces spectral imaging capabilities designed to support tissue characterization and streamline CT workflows.
In a 200-patient study, photon-counting CT reduced radiation exposure while improving detection of malignant features.
Read MoreThe latest PET/MR system combines digital PET and 3T MR technologies with automation tools to streamline acquisition and setup.
Read MoreThe system incorporates CT-guided radiation therapy and AI-enhanced imaging intended to support daily image guidance and treatment visualization.
Read MoreThe system is designed to provide radiologists with procedural flexibility and intraprocedural control across different breast imaging modalities.
Read MoreThe virtually helium-free 1.5T system is designed to lower operating costs while supporting a range of MR applications.
Read More